284 related articles for article (PubMed ID: 17289397)
1. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin.
Zuccaro P; Mombelli G; Calabresi L; Baldassarre D; Palmi I; Sirtori CR
Pharmacol Res; 2007 Apr; 55(4):310-7. PubMed ID: 17289397
[TBL] [Abstract][Full Text] [Related]
2. Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients.
Berta E; Harangi M; Zsíros N; Nagy EV; Paragh G; Bodor M
Pharmazie; 2014 Jun; 69(6):420-3. PubMed ID: 24974574
[TBL] [Abstract][Full Text] [Related]
3. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
[TBL] [Abstract][Full Text] [Related]
5. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge.
Fung EC; Crook MA
Cardiovasc Ther; 2012 Oct; 30(5):e212-8. PubMed ID: 21884002
[TBL] [Abstract][Full Text] [Related]
6. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
[TBL] [Abstract][Full Text] [Related]
7. Incidence of skeletal muscle disorders after statins' treatment: consequences in clinical and EMG picture.
Drobny M; Pullmann R; Odalos I; Skerenova M; Saniova B
Neuro Endocrinol Lett; 2014; 35(2):123-8. PubMed ID: 24878976
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition.
Hu M; Mak VW; Tomlinson B
J Clin Pharm Ther; 2011 Jun; 36(3):419-25. PubMed ID: 21545622
[TBL] [Abstract][Full Text] [Related]
9. Drug-drug interactions that interfere with statin metabolism.
Hirota T; Ieiri I
Expert Opin Drug Metab Toxicol; 2015; 11(9):1435-47. PubMed ID: 26058399
[TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
11. [Statin therapy and muscle disorders].
Abel T; Fehér J
Orv Hetil; 2009 Feb; 150(6):261-3. PubMed ID: 19179258
[No Abstract] [Full Text] [Related]
12. No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia.
Ragia G; Kolovou V; Tavridou A; Elens L; Tselepis AD; Elisaf M; Van Schaik RH; Kolovou G; Manolopoulos VG
Drug Metab Pers Ther; 2015 Mar; 30(1):43-8. PubMed ID: 25274942
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
Stein EA; Ballantyne CM; Windler E; Sirnes PA; Sussekov A; Yigit Z; Seper C; Gimpelewicz CR
Am J Cardiol; 2008 Feb; 101(4):490-6. PubMed ID: 18312764
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
[TBL] [Abstract][Full Text] [Related]
15. Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population.
Buzková H; Pechandová K; Danzig V; Vareka T; Perlik F; Zak A; Slanar O
Med Sci Monit; 2012 Aug; 18(8):CR512-517. PubMed ID: 22847201
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors.
Vermes A; Vermes I
Am J Cardiovasc Drugs; 2004; 4(4):247-55. PubMed ID: 15285699
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
Insull W; Black D; Dujovne C; Hosking JD; Hunninghake D; Keilson L; Knopp R; McKenney J; Stein E; Troendle AJ
Arch Intern Med; 1994 Nov; 154(21):2449-55. PubMed ID: 7979841
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6*4 polymorphism is associated with statin-induced muscle effects.
Frudakis TN; Thomas MJ; Ginjupalli SN; Handelin B; Gabriel R; Gomez HJ
Pharmacogenet Genomics; 2007 Sep; 17(9):695-707. PubMed ID: 17700359
[TBL] [Abstract][Full Text] [Related]
19. Chronic cough as a complication of treatment with statins: a case report.
Psaila M; Fsadni P; Montefort S
Ther Adv Respir Dis; 2012 Aug; 6(4):243-6. PubMed ID: 22761129
[TBL] [Abstract][Full Text] [Related]
20. Risk identification and possible countermeasures for muscle adverse effects during statin therapy.
Magni P; Macchi C; Morlotti B; Sirtori CR; Ruscica M
Eur J Intern Med; 2015 Mar; 26(2):82-8. PubMed ID: 25640999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
